Misplaced advocacy: What does better hepatitis C treatment really mean?
- PMID: 26243815
- PMCID: PMC4610829
- DOI: 10.1503/cmaj.150612
Misplaced advocacy: What does better hepatitis C treatment really mean?
Comment in
-
Well-placed advocacy.CMAJ. 2016 Oct 18;188(15):1106. doi: 10.1503/cmaj.1150123. CMAJ. 2016. PMID: 27754884 Free PMC article. No abstract available.
References
-
- Drugs and health products: Sovaldi. Ottawa: Health Canada; 2015. [updated]. Available: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_sovaldi... (accessed 2015 July 16).
-
- Summary Basis of Decision (SBD) for Harvoni. Ottawa: Health Canada; 2015. [updated]. Available: www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2015_harvoni... (accessed 2015 July 16).
-
- US Food and Drug Administration approves Gilead’s Sovaldi (sofosbuvir) for the treatment of chronic hepatitis C [press release]. Foster City (CA): Gilead; 2013. Available: www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administrati... (accessed 2015 July 16).
-
- Pollack A. Sales of Sovaldi, new Gilead hepatitis C drug, soar to $10.3 billion. New York Times 2015. Feb. 3 Available: www.nytimes.com/2015/02/04/business/sales-of-sovaldi-new-gilead-hepatiti... (accessed 2015 July 16).
-
- Hepatitis C: quick facts. Ottawa: Public Health Agency of Canada; 2014. [modified]. Available: www.phac-aspc.gc.ca/hepc/index-eng.php (accessed 2015 July 16).
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical